Regarding TP53, somatic TP53 status is used in routine clinical practice in several types of cancer such as chronic lymphocytic leukemia (CLL) [64], acute myeloid leukemia (AML) [65] and myelodysplastic syndrome, in order to identify patients likely to benefit from specific treatments. This evidence concerns the gene TP53 and myelodysplastic syndrome.